General Information of the Compound
Compound ID
CP0152575
Compound Name
N-cyclohexyl-3-[2-(3,4-dichlorophenyl)ethylamino]-N-[2-[2-(5-hydroxy-3-oxo-4H-1,4-benzoxazin-8-yl)ethylamino]ethyl]propanamide
    Show/Hide
Synonyms
AZ 505
AZ-505
AZ505
    Show/Hide
Structure
Formula
C29H38Cl2N4O4
Molecular Weight
577.553
Canonical SMILES
Oc1ccc(CCNCCN(C2CCCCC2)C(=O)CCNCCc2ccc(Cl)c(Cl)c2)c2OCC(=O)Nc12
    Show/Hide
InChI
InChI=1S/C29H38Cl2N4O4/c30-23-8-6-20(18-24(23)31)10-13-32-15-12-27(38)35(22-4-2-1-3-5-22)17-16-33-14-11-21-7-9-25(36)28-29(21)39-19-26(37)34-28/h6-9,18,22,32-33,36H,1-5,10-17,19H2,(H,34,37)
    Show/Hide
InChIKey
LIBVHXXKHSODII-UHFFFAOYSA-N
Physicochemical Property
logP
4.5457
Rotatable Bonds
13
Heavy Atom Count
39
Polar Areas
102.93
Hydrogen Bond Donor Count
4
Hydrogen Bond Acceptor Count
6
Complexity
39

"RO5" indicates the cutoff set by lipinski's rule of five:

(1) Molecular weight less than 500 Dalton;

(2) xlogp less than 5;

(3) No more than 5 hbonddonor (Hydrogen Bond Donor Count);

(4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count);

(5) No more than 10 rotbonds (Rotatable Bond Count).

    Show/Hide
Click to Show/Hide the External Link(s) of This Compound
PubChem ID
CID: 24961094
SID: 56258966
ChEMBL ID
CHEMBL2169920
Clinical Information about the Compound
Drug 1 ( AZ505 )
Drug Name AZ505
Indication
Solid tumour/cancer
Preclinical
Target(s)
SET and MYND domain-containing protein 2 (SMYD2)
Inhibitor